

Received 2023-02-21

Revised 2023-03-06

Accepted 2023-03-11

Heme Oxygenase-1 (HMOX1) Gene Polymorphisms, Thrombosis and COVID-19: Correspondence

Rujittika Mungmunpantipantip¹✉, Viroj Wiwanitkit²¹ Private Academic Consultant, Bangkok, Thailand² Chandigarh University, Punjab, India; Adjunct professor, Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria*Dear editor,*

We would like to share ideas on the publication “Heme Oxygenase-1 (HMOX1) Gene Polymorphisms as Predictive Markers of Increased Risk of Thrombosis among Patients with Coronavirus disease 2019 (COVID-19) [1].” According to Shakir Mohammed *et al.*, identifying patients at high risk for HMOX-1 pathway activation and thrombosis as well as determining the relationship between HMOX-1 promoter polymorphisms and disease severity and increased risk of thrombosis among COVID19 black patients may be helpful in developing a treatment plan to prevent COVID-19 complications. The hypothesis that HMOX-1 pathway activation and thrombosis are connected to greater morbidity in blacks is presented in the publication by Shakir Mohammed *et al.*

We disagree with them. This article’s discussion of inherited traits may or may not be relevant. We both agree that the genetic component under investigation may be connected to the desired result. The severity of COVID-19 is, however, correlated with a number of genetic differences, such as TMPRSS2, interleukin 1B, TMPRSS2, and HLA polymorphisms [2-5]. Also, there’s a probability that the current asymptomatic COVID-19 is related to a former clinical manifestation of the illness. The consequences of unanticipated, potentially puzzling genetic alterations should be the focus of future research. In conclusion,

Shakir Mohammed *et al.*’s study on a single genetic variant and conclusion for the interrelationship is still too preliminary, and there may be confounders that can contribute to the severity.

According to Shakir Mohammed *et al.*’s report, HMOX-1 gene polymorphism in blacks may be one of the causes, but it could also be due to other uninvestigated genetic factors, as previously mentioned. As evidence, in an experimental study in which the HMOX-1 gene polymorphism was evaluated for its relationship with disease severity, it was discovered that there is also an impact from other important genetic polymorphisms such as NRF2, NQO1, and MT at the same time [6]. As a result, Shakir Mohammed *et al.*’s study on a single genetic variant and conclusion for the interrelationship is still too preliminary, and there may be confounders that cause the conclusion to be invalid. A study on a single genetic variant and then drawing conclusions about the association is a common pitfall if the potential effect of other genetic variants is not considered. [GMJ.2023;12:e2952]

DOI:[10.31661/gmj.v12i0.2952](https://doi.org/10.31661/gmj.v12i0.2952)

Conflict of Interest

None.

Keywords: Heme Oxygenase-1; Thrombosis; COVID-19

GMJ

Copyright© 2021, Galen Medical Journal.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution 4.0 International License
(<http://creativecommons.org/licenses/by/4.0/>)
Email:info@gmj.ir



✉ **Correspondence to:**
Rujittika Mungmunpantipantip, Private Academic Consultant, Bangkok, Thailand.
Telephone Number: +662246641336
Email Address: rujittika@gmail.com

References

1. Shakir Mohammed M, Abdelsamea Mohamedahmed K. Heme Oxygenase-1 (HMOX1) Gene Polymorphisms as Predictive Markers of Increased Risk of Thrombosis among Patients with COVID-19. *Galen Med J.* 2022 Nov 16;11:e2398.
2. Kaidashev I, Izmailova O, Shlykova O, Kabaliev A, Vatsenko A, Ivashchenko D, Dudchenko M, Volianskyi A, Zelinskyy G, Koval T, Dittmer U. Polymorphism of *tmprss2* (rs12329760) but not *ace2* (rs4240157), *tmprss11a* (rs353163) and *cd147* (rs8259) is associated with the severity of COVID-19 in the Ukrainian population. *Acta Biomed.* 2023 Feb 13;94(1):e2023030.
3. Akcay OF, Yeter HH, Unsal Y, Yasar E, Gonen S, Derici U. Impact of HLA polymorphisms on the susceptibility to SARS-CoV-2 infection and related mortality in patients with renal replacement therapy. *Hum Immunol.* 2023 Feb 6:S0198-8859(23)00023-X.
4. Galán-Huerta KA, Zamora-Márquez MA, Flores-Pérez RO, Bocanegra-Ibarias P, Salas-Treviño D, Rivas-Estilla AM. Association of the Interleukin 1B-31*C Proinflammatory Allele with the Severity of COVID-19 Patients A Preliminary Report. *Viral Immunol.* 2023;0(0):.
5. Yaghoobi A, Lord JS, Rezaiezhadeh JS, Yekaninejad MS, Amini M, Izadi P. *TMPRSS2* polymorphism (rs12329760) and the severity of the COVID-19 in Iranian population. *PLoS One.* 2023;18(2):e0281750.
6. Sarutipai boon I, Settasatian N, Komansin N, Kukongwiriyan U, Sawanyawisuth K, Intharaphet P, Senthong V, Settasatian C. Association of Genetic Variations in *NRF2*, *NQO1*, *HMOX1*, and *MT* with Severity of Coronary Artery Disease and Related Risk Factors. *Cardiovasc Toxicol.* 2020;20(2):176-189.